EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting
EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting
复制标题
DOI：
10.1007/s00259-010-1549-3
复制
发表时间：
2011-01-01
影响因子：
9.1
通讯作者：
Bardies, M.
中科院分区：
文献类型：
--
作者：
Lassmann, M.;Chiesa, C.;Bardies, M.
核医学的许多最新出版物包含现有的和新的诊断和治疗剂的剂量测定结果的数据。然而，在许多这些文章中，缺乏对剂量测定方法的描述，或者省略了重要的细节。EANM剂量测定委员会的目的是指导读者通过一系列建议报告剂量测定方法。作者意识到报告给定临床剂量测定程序的实施方式需要大量数据。本指南文件的另一个目的是为编写和提交包含内剂量测定数据的出版物和报告提供全面的信息。本指导文件还包含一份核对表，可供科学期刊投稿或申请资助的审稿人参考。此外，本文件可用于确定哪些数据可用于记录个体患者记录中的剂量测定结果。当设想由诸如EMA或FDA的官方机构批准新的放射性药物时，这可能是重要的。
Many recent publications in nuclear medicine contain data on dosimetric findings for existing and new diagnostic and therapeutic agents. In many of these articles, however, a description of the methodology applied for dosimetry is lacking or important details are omitted. The intention of the EANM Dosimetry Committee is to guide the reader through a series of suggestions for reporting dosimetric approaches. The authors are aware of the large amount of data required to report the way a given clinical dosimetry procedure was implemented. Another aim of this guidance document is to provide comprehensive information for preparing and submitting publications and reports containing data on internal dosimetry. This guidance document also contains a checklist which could be useful for reviewers of manuscripts submitted to scientific journals or for grant applications. In addition, this document could be used to decide which data are useful for a documentation of dosimetry results in individual patient records. This may be of importance when the approval of a new radiopharmaceutical by official bodies such as EMA or FDA is envisaged.